Incyte Corp. buy stratec
Start price
19.02.20
/
50%
€75.44
Target price
04.11.21
€100.00
Performance (%)
-22.53%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The prediction for Incyte Corp. disappointed with a performance of -22.53%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | 0.094% | 0.094% | 62.176% | 40.649% |
| iShares Core DAX® | 4.642% | 7.489% | 6.987% | 53.734% |
| iShares Nasdaq 100 | 4.471% | 16.803% | 40.281% | 104.329% |
| iShares Nikkei 225® | 7.670% | 16.856% | 47.874% | 73.793% |
| iShares S&P 500 | 2.472% | 9.903% | 28.430% | 72.579% |
Comments by stratec for this prediction
In the thread Incyte Corp. diskutieren
Incyte (NASDAQ:INCY) perks up 2% premarket on light volume on the heels of its announcement of positive results from a second Phase 3 clinical trial, TRuE-AD1, evaluating ruxolitinib cream 0.75% or 1.5% in patients at least 12 years old with mild-to-moderate atopic dermatitis (AD). The study met the primary endpoint of a statistically significant proportion of treated patients achieving clear or almost clear skin at week 8 compared to vehicle (placebo). A sister Phase 3, TRuE-AD2, was also successful. Marketing applications should be the next step.
Kursziel geändert auf 100,0
In the thread Trading Incyte Corp.
Die von stratec gewählte maximale Laufzeit wurde überschritten